Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer

Journal of Clinical Pathology

Volumn 55, Issue 7, 2002, Pages 508-513

  Selli, C ^a,n   Montironi, R ^b   Bono, A ^c   Pagano, F ^d   Zattoni, F ^e   Manganelli, A ^f   Selvaggi, F P ^g   Comeri, G C ^h   Fiaccavento, G ⁱ   Guazzieri, S ^j   Lembo, A ^k   Cosciani Cunico, S ^l   Potenzoni, D ^m   Muto, G ⁿ   Mazzucchelli, R ^b   Santinelli, A ^b   Polito, M ⁿ   Muzzonigro, G ⁿ   Minardi, D ⁿ   Palazzo, S ⁿ   Bufo, P ⁿ   Bertoldin, R ⁿ   Doglioni, C ⁿ   Macri E ⁿ   Canclini, L ⁿ   Chinagila, D ⁿ   Zambolin, T ⁿ   Tanello, M ⁿ   Tardanico, R ⁿ   Usoi, E ⁿ   Migliari, R ⁿ   Muscas, G ⁿ   Valdes, E ⁿ   Varsi, C ⁿ   Ferretti, S ⁿ   Palladini, P ⁿ   DiGregorio, C ⁿ   Conti, G ⁿ   Lunetta, Q ⁿ   Scola, G ⁿ   Signorelli, G ⁿ   Andretta, E ⁿ   Giordano, R ⁿ   Nisi, E ⁿ   Rizzo, M ⁿ   Bartoletti, R ⁿ   Amorosi, A ⁿ   Martini, E ⁿ   Andreassi, P ⁿ   Ventura, T ⁿ   Artibani, W ⁿ   Piazza, R ⁿ   de Gaetoni, C ⁿ   Fontana, D ⁿ   Tarabuzzi, R ⁿ   Gulbetta, L ⁿ   Bollito, E ⁿ   Prayer Galetti, T ⁿ   Gardiman, M ⁿ   Belmonte, P ⁿ   Sacchi, G ⁿ   Rocco Rossetti, S ⁿ   Terrone, C ⁿ   Palestro, G ⁿ   Galliano, D ⁿ   Bardari, F ⁿ   Campobasso, O ⁿ   Pisacane, A M ⁿ   de Rubertis, G ⁿ   Del Vecchio, M T ⁿ   Gregori, A ⁿ   Serra, L ⁿ   Anselmo, G ⁿ   Checchin, A ⁿ   Arrigoni, G A ⁿ   Scott, C ⁿ   Beltrami, C A ⁿ   Galassi, P ⁿ   Comeri, G ⁿ   Bono, A V ⁿ   Fava, C ⁿ   Salvadore, M ⁿ   Tasca, A ⁿ   Meneghini, A ⁿ   Meli, S ⁿ   Armani, A ⁿ   more..

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Division of Urology   (Italy)

^f Division of Urology   (Italy)

^g UNIVERSITY OF BARI   (Italy)

^h Division of Urology   (Italy)

ⁱ Division of Urology   (Italy)

^j Division of Urology   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l Division of Urology   (Italy)

^m MOLINETTE HOSPITAL   (Italy)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0036064404     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.55.7.508     Document Type: Article

References (23)

1. Pathological changes in prostate lesions after androgen manipulation
2. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma
3. Neoadjuvant hormonal therapy: The Canadian experience
4. Random prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
5. The risk of malignancy in the surgical margin at radical prostatectomy is reduced almost three-fold in patients given neoadjuvant hormone treatment
6. Randomized study of neoadjuvant androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer
7. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer
8. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial
9. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3 N0M0 prostate cancer
10. Update on Memorial Sloan-Kettering Cancer Center studies on neoadjuvant hormonal therapy for prostate cancer
11. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
12. Neoadjuvant hormonal therapy prior to surgery for prostate carcinoma: The Italian experience (PROSIT study)
13. Therapy of prostatic cancer and histopathologic follow-up
14. High Gleason score predicts poor pathologic outcome after neoadjuvant androgen deprivation for locally advanced prostate cancer
15. Neoadjuvant combined androgen deprivation therapy in locally confined prostate carcinoma: Short-term results of a European randomized study
16. Neoadjuvant androgen ablation therapy prior to radical prostatectomy: Quantum leap or hope unrealised?
17. Neoadjuvant hormonal treatment before radical prostatectomy
18. Impact of radical prostatectomy in the management of clinically localized disease
19. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary
20. Neoadjuvant hormonal treatment prior to radical prostatectomy: Facts and questions
21. The indications, rationale and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer
22. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects
23. Prolonged combined androgen blockade leads to a further reduction of prostatic tumor volume: Three versus six months of endocrine therapy